Back to Search Start Over

Risk of Persistent Disability in Patients with Pediatric-Onset Multiple Sclerosis

Authors :
Baroncini, D
Simone, M
Iaffaldano, P
Brescia Morra, V
Lanzillo, R
Filippi, M
Romeo, M
Patti, F
Chisari, C
Cocco, E
Fenu, G
Salemi, G
Ragonese, P
Inglese, M
Cellerino, M
Margari, L
Comi, G
Zaffaroni, M
Ghezzi, A
Cavaletti, G
Baroncini D.
Simone M.
Iaffaldano P.
Brescia Morra V.
Lanzillo R.
Filippi M.
Romeo M.
Patti F.
Chisari C. G.
Cocco E.
Fenu G.
Salemi G.
Ragonese P.
Inglese M.
Cellerino M.
Margari L.
Comi G.
Zaffaroni M.
Ghezzi A.
Cavaletti G.
Baroncini, D
Simone, M
Iaffaldano, P
Brescia Morra, V
Lanzillo, R
Filippi, M
Romeo, M
Patti, F
Chisari, C
Cocco, E
Fenu, G
Salemi, G
Ragonese, P
Inglese, M
Cellerino, M
Margari, L
Comi, G
Zaffaroni, M
Ghezzi, A
Cavaletti, G
Baroncini D.
Simone M.
Iaffaldano P.
Brescia Morra V.
Lanzillo R.
Filippi M.
Romeo M.
Patti F.
Chisari C. G.
Cocco E.
Fenu G.
Salemi G.
Ragonese P.
Inglese M.
Cellerino M.
Margari L.
Comi G.
Zaffaroni M.
Ghezzi A.
Cavaletti G.
Publication Year :
2021

Abstract

Importance: Availability of new disease-modifying therapies (DMTs) and changes of therapeutic paradigms have led to a general improvement of multiple sclerosis (MS) prognosis in adults. It is still unclear whether this improvement also involves patients with pediatric-onset MS (POMS), whose early management is more challenging. Objective: To evaluate changes in the prognosis of POMS over time in association with changes in therapeutic and managing standards. Design, Setting, and Participants: Retrospective, multicenter, observational study. Data were extracted and collected in May 2019 from the Italian MS Registry, a digital database including more than 59000 patients. Inclusion criteria were MS onset before age 18 years, diagnosis before January 2014, and disease duration of at least 3 years. Exclusion criteria were primary progressive MS, Expanded Disability Status Scale (EDSS) score of at least 8 one year after onset, unavailability of diagnosis date, and less than 2 EDSS score evaluations. Eligible patients were 4704 patients with POMS. According to these criteria, we enrolled 3198 patients, excluding 1506. Exposures: We compared time to reach disability milestones by epoch of MS diagnosis (<1993, 1993-1999, 2000-2006, and 2007-2013), adjusting for possible confounders linked to EDSS evaluations and clinical disease activity. We then analyzed the difference among the 4 diagnosis epochs regarding demographic characteristics, clinical disease activity at onset, and DMTs management. Main Outcomes and Measures: Disability milestones were EDSS score 4.0 and 6.0, confirmed in the following clinical evaluation and in the last available visit. Results: We enrolled 3198 patients with POMS (mean age at onset, 15.2 years; 69% female; median time to diagnosis, 3.2 years; annualized relapse rate in first 1 and 3 years, 1.3 and 0.6, respectively), with a mean (SD) follow-up of 21.8 (11.7) years. Median survival times to reach EDSS score of 4.0 and 6.0 were 31.7 and 40.5 ye

Details

Database :
OAIster
Notes :
STAMPA, English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1313115402
Document Type :
Electronic Resource